Current evidence on the impact of medication optimization or pharmacological interventions on frailty or aspects of frailty
a systematic review of randomized controlled trials
Farhad Pazan (University of Heidelberg)
Mirko Petrovic (Universiteit Gent)
Antonio Cherubini (IRCCS-INRCA)
Graziano Onder (ISS - Istituto Superiore di Sanità)
Alfonso J. Cruz‑Jentoft (Hospital Universitario Ramón y Cajal)
Michael Denkinger (University of Ulm and Geriatric Center Ulm/Alb-Donau)
TJM Van Der Cammen (TU Delft - Human Factors)
Jennifer Stevenson (King’s College London)
Kinda Ibrahim (University of Southampton, Faculty of Medicine)
More Authors (External organisation)
More Info
expand_more
Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.
Abstract
Background: Frailty and adverse drug effects are linked in the fact that polypharmacy is correlated with the severity of frailty; however, a causal relation has not been proven in older people with clinically manifest frailty. Methods: A literature search was performed in Medline to detect prospective randomized controlled trials (RCTs) testing the effects of pharmacological interventions or medication optimization in older frail adults on comprehensive frailty scores or partial aspects of frailty that were published from January 1998 to October 2019. Results: Twenty-five studies were identified, 4 on comprehensive frailty scores and 21 on aspects of frailty. Two trials on comprehensive frailty scores showed positive results on frailty although the contribution of medication review in a multidimensional approach was unclear. In the studies on aspects related to frailty, ten individual drug interventions showed improvement in physical performance, muscle strength or body composition utilizing alfacalcidol, teriparatide, piroxicam, testosterone, recombinant human chorionic gonadotropin, or capromorelin. There were no studies examining negative effects of drugs on frailty. Conclusion: So far, data on a causal relationship between drugs and frailty are inconclusive or related to single-drug interventions on partial aspects of frailty. There is a clear need for RCTs on this topic that should be based on a comprehensive, internationally consistent and thus reproducible concept of frailty assessment.